Recent Finacing
Recent Raise
Tiltan Pharma, based in Jerusalem, develops TL-118—an oral once-daily anti-angiogenic combination therapy for cancer—conducting randomized Phase 2 trials in metastatic pancreatic cancer after Phase 1 safety data.
Focus Areas
Total Raised
Funding round